Co-development of a nanomedicine treatment and companion diagnostic test for castration-resistant prostate cancer

Recognition: NWOVeniScientific

Description

Prostate cancer (PC) is one of the deadliest types of cancer in males worldwide. Early stage PC is often curable but many patients develop castration-resistant prostate cancer (CRPC), resulting in lethal end-stage disease. Prostate specific antigen (PSA) plasma levels have been traditionally exploited for diagnosis and prognosis. However, PSA screening is characterized by high variability leading to false-positive outcomes. Advanced therapies are required for the treatment of CRPC, guided by a reliable companion diagnostic test (CDx) for patient selection and to monitor therapeutic efficacy. The aim of this proposal is to co-develop for the first time a nanomedicine combination therapy and a CDx based on extracellular vesicles (EVs) for the treatment of CRPC. I will employ tumor-targeted nanomedicines to deliver more drug to the tumor and reduce side
effects when compared to free drug. The treatment comprises microfluidics-prepared lipid nanoparticles (LNPs) containing siRNAs that target essential CRPC genes, combined with LNPs loaded with the cytotoxic anti-cancer agent docetaxel to achieve synergistic therapeutic effects. Regarding the CDx, EVs have created excitement as potential biomarker candidates. EVs are released by cells as means of intercellular communication and can be detected in bodily fluids. The number of EVs and their composition is altered in CRPC, raising opportunities to exploit them in a CDx. As EVs provide a fingerprint of
their parental cell, EVs can be considered as liquid biopsies which provide more
information than standard biomarker measurements and are much less invasive than prostate biopsies. I will collect blood and urine samples during the preclinical evaluation of the proposed treatment for EV analysis by surface markers, protein content and RNA content. The co-development of a nanomedicine combination treatment for CRPC and a CDx is a rational strategy that has the potential to advance into clinical evaluation and
ultimately improve patient survival.
Degree of recognitionNational

Fingerprint

Nanomedicine
Castration
Routine Diagnostic Tests
Prostatic Neoplasms
docetaxel
Therapeutics
Prostate-Specific Antigen
Nanoparticles
Neoplasms
Biomarkers
Lipids
Biopsy
Microfluidics
Neoplasm Genes
Dermatoglyphics
Therapeutic Uses
Extracellular Vesicles
Pharmaceutical Preparations
Patient Selection
Prostate